+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Breast Cancer Therapeutics Market to be Dominated by HER2 Inhibitors

Posted on Nov 25, 2015

Transparency Market Research has published a new market report titled, “Breast Cancer Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023.” According to the report, the global breast cancer market was valued at US$7.1 bn in 2014 and is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$16.2 bn by 2023.

Browse the full Breast Cancer Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023 report at http://www.transparencymarketresearch.com/breast-cancer-therapeutics-pipeline-analysis-market.html

 

HER2 receptor type cancer is the most invasive form of breast cancer. It can be easily detected and treated due to the advancement in companion testing and targeted therapies. Drugs used to treat this type of cancer are often biological and have dominated the market. This report provides current trends and proximate analysis of the major therapies used to treat breast cancer, segmenting them based on type of drug class. Drugs have been analyzed by segments such as HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors hormones, and hormone receptors. HER2 inhibitors was the largest segment of the global breast cancer therapeutics market in 2014. The segment is expected to dominate the market during the forecast period. Herceptin, followed by Perjeta and Kadcyla, have propelled the breast cancer therapeutics market. The HER2 inhibitors segment was valued at US$ 4,905.5 Mn in 2014 and is likely to account for US$ 9,251.0 Mn by 2023, expanding at a CAGR of 6.2% from 2015 to 2023.

breast-cancer-therapeutics-pipeline-analysis-2015-market

Aromatase inhibitors is projected to be the second largest segment of the breast cancer therapeutics market in terms of revenue from 2015 to 2023. Ibrance is likely to lead the segment due to increase in progression free survival of post-menopausal patients of breast cancer. Hormone receptors  was the third largest segment due to the success of Faslodex in the treatment of hormone receptor positive metastatic breast cancer. The anticipated rise in biosimilars could restrain the market. However, these are likely to be introduced by 2020, thereby having little impact on the market. Ibrance, aromatase inhibitor, is projected to record the fastest growth due to its clinical efficacy in PALOMA-1 trial. The breast cancer therapeutics market is anticipated to be driven by the success of targeted therapies in the treatment of triple negative breast cancer and swift approvals under the accelerated approval program of the U.S. Food Drug Administration.

  1. Hoffmann-La Roche, AstraZeneca plc, Bristol-Myers Squibb, Novartis AG, Eisai Co., Ltd. and Pfizer, Inc. are the major companies operating in the global breast therapeutics market. Genentech, a Roche company, was identified as the leading player in the global breast cancer therapeutics market in 2014, accounting for a share of over 64% in terms of revenue.

The global breast cancer therapeutics market has been segmented as follows:
Global Breast Cancer Therapeutics Market, by Drug Class

  • HER2 Inhibitors
  • Mitotic Inhibitors
  • Anti-metabolites
  • Aromatase Inhibitors
  • Hormone Receptors

Global Breast Cancer Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
  • Asia Pacific
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)

Browse : Our new press releases http://www.transparencymarketresearch.com/pressrelease/global-breast-cancer-therapeutics-pipeline-analysis-market.html?
About Us


Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
 

Contact

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com